research use only

Oleic Acid ATPase activator

Name: Oleic Acid
Brand: Selleck Chemicals
SKU: S4707
Availability: InStock
Rating: 5 (11 reviews)

Cat.No.S4707

Oleic acid (Oleate, 9-Octadecenoic Acid, Elaidoic acid) is a fatty acid that occurs naturally in various animal and vegetable fats and oils. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. Oleic acid is an abundant monounsaturated fatty acid. Oleic acid is a Na+/K+ ATPase activator.Oleic Acid can be used to induce animal models of Renal Failure.

Chemical Structure

Molecular Weight: 282.46

Jump to

Quality Control

Batch: Purity: 99.85%

99.85

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel GluR
Other ATPase Inhibitors	(-)-Blebbistatin Thapsigargin Brefeldin A (BFA chemical) CB-5083 Sodium orthovanadate Golgicide A BTB06584 Ginsenoside Rb1 CDN1163 Periplocin

Solubility

In vitro
Batch:

Ethanol : 100 mg/mL

DMSO : 50 mg/mL (177.01 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (8.85mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (8.85mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	282.46	Formula	C₁₈H₃₄O₂	Storage (From the date of receipt)	2 years -20°C liquid
CAS No.	112-80-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

In vitro	Oleic acid treatment induces a marked increase in the proliferation of 786-O cells in a dose-dependent manner. It delays 786-O cell apoptosis. In 786‑O cells, ILK is upregulated by oleic acid treatment. Oleic acid activates G protein-coupled receptors and phosphorylates ERK1/2 to induce cancer cell proliferation in breast cancer. Oleic acid(as low as 5 M) inhibits the stearic acid-induced increase in intercellular adhesion molecule-1 (ICAM-1) expression. Oleic acid is able to diminish endothelial cell activation, irrespective of the stimulus utilized, by suppressing the upregulation of adhesion molecules. It can protect Chinese hamster ovary cells from palmitate-induced lipotoxicity by promoting triglyceride synthesis within the cells.
In vivo	Oleic acid inhibits in vivo Na/K-ATPase activity in the lungs and induced lung injury. 10 μM oleic acid induces lung edema and inflammation with cell influx, lipid body formation, and leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) production. Oleic acid ameliorates amyloidosis in mouse models of Alzheimer's disease.
References	[1] https://pubmed.ncbi.nlm.nih.gov/23599801/ [2] https://pubmed.ncbi.nlm.nih.gov/20852092/ [3] https://pubmed.ncbi.nlm.nih.gov/24175969/ [4] https://pubmed.ncbi.nlm.nih.gov/21040071/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06274788	Not yet recruiting	Parenteral Nutrition Associated Liver Disease (PNALD)\|Essential Fatty Acid Deficiency\|Malnutrition\|Pediatric ALL	Fresenius Kabi	May 1 2024	Phase 4
NCT05556967	Completed	Adherence Patient	University of Mississippi Medical Center\|University of Mississippi National Center for Natural Products Research\|National Center for Complementary and Integrative Health (NCCIH)	August 9 2023	Not Applicable
NCT04614233	Active not recruiting	Overweight and Obesity	Yale University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	April 6 2021	Phase 4
NCT04053569	Unknown status	Metabolic Syndrome Protection Against	Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis	October 1 2019	Not Applicable
NCT05791370	Completed	Diet\|Healthy	Malaysia Palm Oil Board\|Universiti Putra Malaysia	January 1 2019	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):